We performed molecular genetic analysis of 24 subjects from 19 families with 17-hydroxylase deficiency in Brazil. Of 7 novel CYP17 mutations, 2 (W406R and R362C) account for 50% and 32% of the mutant alleles, respectively. Both mutations were completely inactive when studied in COS-7 cells and yeast microsomes; however, phenotypic features varied among subjects. Some 46,XY individuals with these genotypes had ambiguous genitalia, and other subjects had normal blood pressure and/or serum potassium. We found mutations W406R and R362C principally in families with Spanish and Portuguese ancestry, respectively, suggesting that two independent founder effects contribute to the increased prevalence of 17-hydroxylase deficiency in Brazil. Mutations Y329D and P428L retained a trace of activity, yet the two individuals with these mutations had severe hypertension and hypokalemia. The 46,XX female with mutation Y329D reached Tanner stage 5, whereas the 46,XY subject with mutation P428L remained sexually infantile. The severity of hypertension, hypokalemia, 17-deoxysteroid excess, and sex steroid deficiency varied, even among patients with completely inactive CYP17 protein(s). Spontaneous sexual development occurred only in 46,XX females with partial deficiencies. We conclude that other factors, in addition to CYP17 genotype, contribute to the phenotype of individual patients with 17-hydroxylase deficiency.

To date, only two among 46 mutations in the CYP17 gene cause 17-hydroxylase deficiency (17OHD) by disrupting mRNA splice donor sites. We studied two subjects with intronic CYP17 mutations: a compound heterozygote for Y329D plus an AG to CG substitution at the 3' end of intron 2, and a homozygote for a TTTT deletion near the 3' end of intron 3. We hypothesized that both mutations caused 17OHD by disrupting splice acceptor sites. To prove this mechanism, the entire CYP17 genes (wild type and both mutations) were amplified, subcloned into pcDNA3, and expressed in HEK-293 cells. The mRNA derived from the wild-type CYP17 gene was correctly spliced and translated into active enzyme, as shown by the correct sequence in the RT-PCR products and by the 17-hydroxylation of progesterone. In contrast, cells expressing the mutant genes had no 17-hydroxylase activity. The mRNA derived from the AG to CG mutation used the first AG in exon 3 as the splice acceptor site, shifting the reading frame and introducing a stop codon. RNA derived from the TTTT deletion skipped exon 4 entirely, deleting 29 amino acids in-frame. Our data show that these are the first two 17OHD cases resulting from mutations that alter splice acceptor sites. These studies also demonstrate the feasibility of expressing the entire CYP17 gene, with simultaneous protein and RNA analysis, as a general methodology for characterizing how intronic CYP17 mutations cause 17OHD.

No abstract

RESUMOHiperplasia adrenal congênita (HAC) é uma doença autossômica recessiva decorrente da alteração de enzimas que participam da síntese do cortisol. As manifestações podem ser causadas pela deficiência do cortisol e, em alguns casos, aldosterona e pelo acúmulo de precursores. O objetivo desta revisão é apresentar os mecanismos moleculares dos principais defeitos enzimáticos envolvidos na etiopatogênese da HAC. A deficiência da 21-hidroxilase (21OH) ocorre em 95% dos casos de HAC. Existem dois genes que codificam o P450c21: um ativo, CYP21, e um pseudogene CYP21P. Ambos são altamente homólogos (98%), o que favorece o emparelhamento desigual dos cromossomos homólogos durante a meiose, levando a duplicações e/ou deleções ou conversões desses genes. Adicionalmente, foram também descritas mutações de ponto, muitas delas presentes no pseudogene sugerindo microconversões. Mutações no gene CYP11B1 causam HAC por deficiência da 11β-hidroxilase, forma esta que corresponde a 5% dos casos. Algumas mutações são recorrentes, situando-se principalmente entre os exons 6-8 que representaria uma área hot-spot no gene CYP11B1. A deficiência de 17-hidroxilase é causada por mutações no gene CYP17, que codificam uma proteína alterada, levando a deficiência total ou parcial de 17-hidroxilação e 17,20-liase ou deficiência isolada de 17,20-liase. Finalmente, deficiência de 3β-HSD é causada por mutações no gene HSD3B2, que codifica a enzima 3β-HSD tipo II e estas mutações têm sido associadas tanto com a forma clássica como com a forma não clássica da deficiência da 3β-HSD. Congenital adrenal hiperplasia (CAH) is a recessive autossomic disease caused by inherited defects in cortisol biosynthesis. The manifestations are caused both by the deficient synthesis of cortisol, and sometimes of aldosterone, and by accumulation of the precursor steroids. The objective of this review is to present the molecular mechanisms of the main enzymatic defects involved in the etiopathogenesis of CAH. Deficiency of 21-hydroxylase (21OH) accounts for more than 95% of all cases of CAH. The human genome contains two CYP genes: one active, CYP21, and a pseudogene, CYP21P. Both are highly homologous (98%), facilitating recombination events during meiosis, leading to duplication and/or deletion or conversion of these genes. Additionally, point mutations have also been described. Deficiency of 11β-hydroxylase (11βOH) is caused by mutations in the CYP11B1 gene, and accounts for 5% of all cases. Some mutations are recurrent, and mainly located on exons 6-8, which is considered a hot-spot area in CYP11B1 gene. Deficiency of 17α-hydroxylase (17OH) is caused by mutations in the CYP17 gene, producing a truncated or impaired protein. These mutations have been described in patients with combined defi-

RESUMOHipertensão arterial não é privilégio de adultos. Além de causas renais e vasculares, doenças adrenocorticais ou correlatas devem ser consideradas na investigação da criança e adolescente hipertensos. O receptor mineralocortidóide (MC) pode ser ativado tanto por MC típicos como pelo cortisol, e mesmo funcionar de maneira autônoma, decorrente de distúrbio nos canais de sódio. Assim, hiperatividade MC (hipertensão, hipocalemia e supressão de renina) pode resultar do excesso de: (1) aldosterona, (2) deoxicorticosterona (DOC) e (3) cortisol. O primeiro grupo, denominado hiperaldosteronismo primário (HAP), inclui o adenoma, o carcinoma e a hiperplasia produtora de aldosterona, além de causa familiares: HA supressível por dexametasona (ou tipo I) e o tipo II. O segundo grupo engloba os tumores produtores tanto de DOC, como de andrógenos ou estrógenos, e a produção de DOC secundária ao excesso de ACTH (síndrome de Cushing, hiperplasia adrenal congênita por deficiência de 11β-e 17α-hidroxilases e síndrome de resistência periférica ao cortisol). Na síndrome do excesso aparente de MC, cortisol age como um MC graças à deficiência congênita ou à inibição (pelo alcaçuz) da enzima 11β-hidroxisteróide desidrogenase, responsável pela oxidação do cortisol em cortisona. Sódio e fluidos podem ser absorvidos nos túbulos renais de forma inapropriada, tanto na síndrome de Liddle (mutações ativadoras do gene do canal epitelial de sódio) como na de Arnold-Healy-Gordon (onde a hiperreabsorção de cloretos e sódio no túbulo renal impede a excreção de H+ e K+, produzindo hipertensão com acidose e hipercalemia). Todo este espectro de doenças adrenais hipertensivas, apesar de pouco prevalentes, deve ser lembrado com possível causa da hipertensão que pode ocorrer na infância e adolescência. ABSTRACTArterial hypertension is not a privilege of adults. Besides renal and vascular causes, adrenocortical and correlated diseases must be considered when investigating a hypertensive child or adolescent. The mineralocorticoid (MC) receptor can be activated by typical MC as well as by cortisol, and even run autonomously, as a result of disturbances in the sodium channel. Thus, MC hyperactivity (hypertension, hypokalemia and renin suppression) may result from excess of: (1) aldosterone, (2) deoxycorticosterone (DOC), and (3) cortisol. The first group, called primary hyperaldosteronism (PHA), includes aldosterone-producing adenoma, carcinoma and hyperplasia, in addition to familial causes: dexamethasone suppressible HA (or type I) and type II familial PAH. The second group encompasses DOC-producing, as well as androgen-and estrogen-producing tumors, and ACTH-dependent DOC hypersecretion (Cushing's syndrome, congenital adrenal hyperplasia due to 11β-and 17α-hydroxylase deficiencies and the syndrome of peripheral cortisol